Thinly traded nano cap Annovis Bio (NYSEMKT:ANVS) rockets 100% premarket on increased volume in reaction to its announcement of Institutional Review Board (IRB) signoff for a 15-site Phase 2 clinical trial evaluating lead candidate ANVS401 in patients with early Alzheimer’s disease and early Parkinson’s disease.
The two-part study will enroll 68 subjects who will receive ANVS401, an inhibitor neurotoxic proteins tau and alpha-synuclein, for four weeks. Topline data should be available in Q1 2021.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.